Biota Holdings Limited operates in the Commercial physical research sector. Biota Holdings Limited is engaged in the drug discovery and clinical development of antiinfectives, suitable for human use and its commercialization. The Company licensed zanamivir, which is a neuraminidase inhibitor (influenza antiviral). Zanamivir is licensed to GlaxoSmithKline and marketed as Relenza. In addition, the Company and Daiichi Sankyo co-own a range of influenza anti-virals, of which the lead product lnavir, is approved for marketing in Japan. Its research breakthroughs include a series of candidate drugs focused on treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. The Company has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In our complete report available for purchase the company is compared to: Sirtex Medical Limited, Mayne Pharma Group Limited and Idt Australia Limited..